Rifaximin in diverticulosis and diverticular disease: a national survey among Italian gastroenterologists and general practitioners.

Autor: Gatta L; Gastroenterology Unit, ASL Toscana Nord-Ovest, Versilia Hospital, 55041, Lido di Camaiore, Italy. gattalg@gmail.com., Bellini M; Gastrointestinal Unit, Department of Translational Sciences and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Scarpignato C; Department of Health Sciences, United Campus of Malta, Msida, Malta., Marrocco W; Primary Care Physician Azienda Sanitaria Locale (ASL), Roma 5, Tivoli, Rome, Italy., Chiriatti A; Primary Care Physician Azienda Sanitaria Locale (ASL), Roma 3, Rome, Italy., Grosso A; Gastrointestinal Unit, Department of Translational Sciences and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Lambiase C; Gastrointestinal Unit, Department of Translational Sciences and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Usai-Satta P; Gastroenterology Unit, Brotzu Hospital, Cagliari, Italy., Vassallo R; Gastroenterology and Endoscopy Unit, Buccheri la Ferla Hospital, Palermo, Italy., Bartoletti P; Primary Care Physician Azienda Sanitaria Locale (ASL), Roma 2, Rome, Italy., Monica F; Gastroenterology and Digestive Endoscopy Unit, Academic Hospital Cattinara, Trieste, Italy., Manta R; Digestive Endoscopy Unit, ASL Toscana Nord-Ovest, 'Spedali Riuniti' Hospital, Livorno, Italy., Scotti S; Primary Care Physician Azienda Sanitaria Locale (ASL), Napoli 1, Naples, Italy., Soncini M; Department of Internal Medicine, 'A. Manzoni' Hospital, Lecco, Italy.
Jazyk: angličtina
Zdroj: Internal and emergency medicine [Intern Emerg Med] 2024 Sep; Vol. 19 (6), pp. 1675-1685. Date of Electronic Publication: 2024 Jun 08.
DOI: 10.1007/s11739-024-03669-6
Abstrakt: The management of patients with diverticular disease remains challenging. The aim of this national survey was to assess how gastroenterologists and general practitioners use rifaximin to manage diverticulosis and diverticular disease. Members of the Italian Association of Hospital Gastroenterologists and Endoscopists (AIGO) and the Italian Federation of General Practitioners (FIMMG) were invited to complete a 39-item online survey concerning the use of rifaximin in five clinical settings: (1) diverticulosis; (2) reducing symptoms in symptomatic uncomplicated diverticular disease; (3) reducing the occurrence of diverticulitis in patients with symptomatic uncomplicated diverticular disease (primary prevention); (4) reducing the recurrence of diverticulitis in patients with previous attacks of diverticulitis (secondary prevention); (5) treatment of uncomplicated acute diverticulitis. A total of 1094 physicians completed the survey. Overall, 25.1%, 83.5%, 68%, 74.2%, and 63% of physicians prescribed rifaximin for the clinical settings 1, 2, 3, 4, and 5, respectively. In each clinical setting, the dosage of rifaximin most frequently used was 800 mg/day, the most common duration of therapy was 7 days, and the cyclic administration of treatment (expressed in months) most frequently used was > 24 months. These results highlight that a reappraisal of the use of rifaximin in patients with diverticulosis and diverticular disease is required to reduce the gap between the evidence available and the daily clinical practice, optimizing also the use of healthcare resources.
(© 2024. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI).)
Databáze: MEDLINE
Externí odkaz: